Physician profile
John J Obrien
NPI 1083689061
$1,444.71
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $159 · 2022: $340 · 2023: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.03 | 2022-2023 | |
| Lilly USA, LLC | $206.90 | 2019-2023 | Mounjaro, Trulicity |
| Pfizer INC. | $197.33 | 2019-2023 | |
| Amgen INC. | $100.66 | 2019-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $84.99 | 2019-2023 | Bexsero, Shingrix |
| Janssen Pharmaceuticals, INC | $84.58 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $79.57 | 2020-2023 | Fasenra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.02 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $64.57 | 2019-2023 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $39.86 | 2022 | |
| Allergan, INC. | $38.22 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $37.27 | 2019 | |
| Bausch Health US, LLC | $36.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.12 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.01 | 2023 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $20.73 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.58 | 2022 | |
| Abbott Laboratories | $16.97 | 2023 | Freestyle Libre 2 |
| Sanofi Pasteur INC. | $16.68 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.56 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.18 | 2023 | Rexulti |
| Dexcom, INC. | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.